JPWO2020119819A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020119819A5 JPWO2020119819A5 JP2021530299A JP2021530299A JPWO2020119819A5 JP WO2020119819 A5 JPWO2020119819 A5 JP WO2020119819A5 JP 2021530299 A JP2021530299 A JP 2021530299A JP 2021530299 A JP2021530299 A JP 2021530299A JP WO2020119819 A5 JPWO2020119819 A5 JP WO2020119819A5
- Authority
- JP
- Japan
- Prior art keywords
- benzamide
- amino
- pyrazol
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 52
- 230000000155 isotopic effect Effects 0.000 claims 48
- 125000001931 aliphatic group Chemical group 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 14
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- -1 4-(5-chloro-2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(cyanomethyl)benzamide (S)-4-( 5-chloro-2-((1-cyclopropyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-N-(1-cyanoethyl)benzamide Chemical compound 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- NYXJYEKPJMJVEG-KRWDZBQOSA-N 4-[2-[[1-(cyanomethyl)pyrazol-4-yl]amino]-5-methylpyrimidin-4-yl]-N-[(1S)-1-cyanopropyl]benzamide Chemical compound CC[C@@H](C#N)NC(=O)C1=CC=C(C=C1)C2=NC(=NC=C2C)NC3=CN(N=C3)CC#N NYXJYEKPJMJVEG-KRWDZBQOSA-N 0.000 claims 1
- XLWBRCPMFJNNOP-AWEZNQCLSA-N 4-[5-chloro-2-[(1-piperidin-4-ylpyrazol-4-yl)amino]pyrimidin-4-yl]-N-[(1S)-1-cyanoethyl]benzamide Chemical compound C[C@@H](C#N)NC(=O)C1=CC=C(C=C1)C2=NC(=NC=C2Cl)NC3=CN(N=C3)C4CCNCC4 XLWBRCPMFJNNOP-AWEZNQCLSA-N 0.000 claims 1
- GWRURUDODBKOHQ-UHFFFAOYSA-N 4-[5-chloro-2-[[1-(1-methylpiperidin-4-yl)pyrazol-4-yl]amino]pyrimidin-4-yl]-N-(cyanomethyl)benzamide Chemical compound C1(N2N=CC(NC3=NC=C(Cl)C(=N3)C3=CC=C(C(=O)NCC#N)C=C3)=C2)CCN(CC1)C GWRURUDODBKOHQ-UHFFFAOYSA-N 0.000 claims 1
- NGSZFJKMKCZQQU-HNNXBMFYSA-N 4-[5-chloro-2-[[1-(1-methylpiperidin-4-yl)pyrazol-4-yl]amino]pyrimidin-4-yl]-N-[(1S)-1-cyanoethyl]benzamide Chemical compound C[C@@H](C#N)NC(=O)C1=CC=C(C=C1)C2=NC(=NC=C2Cl)NC3=CN(N=C3)C4CCN(CC4)C NGSZFJKMKCZQQU-HNNXBMFYSA-N 0.000 claims 1
- YNDBRZVBKISMFS-HNNXBMFYSA-N 4-[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]-N-[(1S)-1-cyanopropyl]benzamide Chemical compound CC[C@@H](C#N)NC(=O)C1=CC=C(C=C1)C2=NC(=NC=C2Cl)NC3=CN(N=C3)CCO YNDBRZVBKISMFS-HNNXBMFYSA-N 0.000 claims 1
- CEEWXNWDFKEUEJ-UHFFFAOYSA-N 4-[5-chloro-2-[[1-(cyanomethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]-N-(cyanomethyl)benzamide Chemical compound N(C=1C=NN(C=1)CC#N)C1=NC(=C(C=N1)Cl)C1=CC=C(C(=O)NCC#N)C=C1 CEEWXNWDFKEUEJ-UHFFFAOYSA-N 0.000 claims 1
- MZTMXHXBETUTEB-LBPRGKRZSA-N 4-[5-chloro-2-[[1-(cyanomethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]-N-[(1S)-1-cyanoethyl]benzamide Chemical compound N(C=1C=NN(C=1)CC#N)C1=NC(=C(Cl)C=N1)C1=CC=C(C(=O)N[C@H](C#N)C)C=C1 MZTMXHXBETUTEB-LBPRGKRZSA-N 0.000 claims 1
- FAAGDKFQFLXRPD-UHFFFAOYSA-N 4-[5-chloro-2-[[1-(oxan-4-yl)pyrazol-4-yl]amino]pyrimidin-4-yl]-N-(cyanomethyl)benzamide Chemical compound C1(N2N=CC(NC3=NC(=C(Cl)C=N3)C3=CC=C(C(=O)NCC#N)C=C3)=C2)CCOCC1 FAAGDKFQFLXRPD-UHFFFAOYSA-N 0.000 claims 1
- HRPOPMKCQKIUAA-AWEZNQCLSA-N 4-[5-chloro-2-[[1-(oxan-4-yl)pyrazol-4-yl]amino]pyrimidin-4-yl]-N-[(1S)-1-cyanoethyl]benzamide Chemical compound C1C(N2N=CC(NC3=NC(=C(C=N3)Cl)C3=CC=C(C(=O)N[C@H](C#N)C)C=C3)=C2)CCOC1 HRPOPMKCQKIUAA-AWEZNQCLSA-N 0.000 claims 1
- SQDFAGOAVHMBJV-KRWDZBQOSA-N 4-[5-chloro-2-[[1-(oxan-4-yl)pyrazol-4-yl]amino]pyrimidin-4-yl]-N-[(1S)-1-cyanopropyl]benzamide Chemical compound C1(N2N=CC(NC3=NC=C(Cl)C(=N3)C3=CC=C(C(=O)N[C@@H](CC)C#N)C=C3)=C2)CCOCC1 SQDFAGOAVHMBJV-KRWDZBQOSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- GVOUFRDXMSZWSI-UHFFFAOYSA-N N-(cyanomethyl)-2-fluoro-4-[5-methyl-2-[[1-(2,2,6,6-tetramethyloxan-4-yl)pyrazol-4-yl]amino]pyrimidin-4-yl]benzamide Chemical compound C1C(N2N=CC(NC3=NC(=C(C=N3)C)C3=CC(F)=C(C(=O)NCC#N)C=C3)=C2)CC(C)(C)OC1(C)C GVOUFRDXMSZWSI-UHFFFAOYSA-N 0.000 claims 1
- OIRPYDJAVJUHPX-UHFFFAOYSA-N N-(cyanomethyl)-4-[5-methyl-2-[[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]benzamide Chemical compound N(C=1C=NN(C=1)CC(F)(F)F)C1=NC(=C(C=N1)C)C1=CC=C(C(=O)NCC#N)C=C1 OIRPYDJAVJUHPX-UHFFFAOYSA-N 0.000 claims 1
- FKUOLCVQIHONCW-UHFFFAOYSA-N N-(cyanomethyl)-4-[5-methyl-2-[[1-(2,2,6,6-tetramethyloxan-4-yl)pyrazol-4-yl]amino]pyrimidin-4-yl]benzamide Chemical compound CC1=CN=C(N=C1C2=CC=C(C=C2)C(=O)NCC#N)NC3=CN(N=C3)C4CC(OC(C4)(C)C)(C)C FKUOLCVQIHONCW-UHFFFAOYSA-N 0.000 claims 1
- IDCIZNUPAPGBSO-UHFFFAOYSA-N N-(cyanomethyl)-4-[5-methyl-2-[[1-(oxan-4-yl)pyrazol-4-yl]amino]pyrimidin-4-yl]benzamide Chemical compound C1(N2N=CC(NC3=NC(=C(C)C=N3)C3=CC=C(C(=O)NCC#N)C=C3)=C2)CCOCC1 IDCIZNUPAPGBSO-UHFFFAOYSA-N 0.000 claims 1
- KGBUZAIXQMDVMI-UHFFFAOYSA-N N-(cyanomethyl)-4-[5-methyl-2-[[1-[1-(1-methylcyclopropanecarbonyl)piperidin-4-yl]pyrazol-4-yl]amino]pyrimidin-4-yl]benzamide Chemical compound C1(C(=O)N2CCC(CC2)N2N=CC(NC3=NC(=C(C=N3)C)C3=CC=C(C(=O)NCC#N)C=C3)=C2)(CC1)C KGBUZAIXQMDVMI-UHFFFAOYSA-N 0.000 claims 1
- WYWVMZSPILFLPV-SFHVURJKSA-N N-[(1S)-1-cyanobutyl]-4-[2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]-5-methylpyrimidin-4-yl]benzamide Chemical compound CCC[C@@H](C#N)NC(=O)C1=CC=C(C=C1)C2=NC(=NC=C2C)NC3=CN(N=C3)CCO WYWVMZSPILFLPV-SFHVURJKSA-N 0.000 claims 1
- XLWCXZSYAOJGCU-AWEZNQCLSA-N N-[(1S)-1-cyanoethyl]-4-[2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]-5-methylpyrimidin-4-yl]benzamide Chemical compound C=1C(=CN(N=1)CCO)NC1=NC=C(C)C(=N1)C1=CC=C(C(=O)N[C@H](C#N)C)C=C1 XLWCXZSYAOJGCU-AWEZNQCLSA-N 0.000 claims 1
- ISRNXJHLMMQDHE-KRWDZBQOSA-N N-[(1S)-1-cyanoethyl]-4-[2-[[1-[1-(2-hydroxyacetyl)piperidin-4-yl]pyrazol-4-yl]amino]-5-methylpyrimidin-4-yl]benzamide Chemical compound C(C(=O)N1CCC(CC1)N1N=CC(NC2=NC(=C(C=N2)C)C2=CC=C(C(=O)N[C@H](C#N)C)C=C2)=C1)O ISRNXJHLMMQDHE-KRWDZBQOSA-N 0.000 claims 1
- ODGPJSSQLYDABJ-KRWDZBQOSA-N N-[(1S)-1-cyanoethyl]-4-[5-methyl-2-[[1-(1-methylpiperidin-4-yl)pyrazol-4-yl]amino]pyrimidin-4-yl]benzamide Chemical compound CC1=CN=C(N=C1C2=CC=C(C=C2)C(=O)N[C@@H](C)C#N)NC3=CN(N=C3)C4CCN(CC4)C ODGPJSSQLYDABJ-KRWDZBQOSA-N 0.000 claims 1
- QNSFQSGKIUOMGL-SFHVURJKSA-N N-[(1S)-1-cyanoethyl]-4-[5-methyl-2-[[1-(2,2,6,6-tetramethyloxan-4-yl)pyrazol-4-yl]amino]pyrimidin-4-yl]benzamide Chemical compound CC1=CN=C(N=C1C2=CC=C(C=C2)C(=O)N[C@@H](C)C#N)NC3=CN(N=C3)C4CC(OC(C4)(C)C)(C)C QNSFQSGKIUOMGL-SFHVURJKSA-N 0.000 claims 1
- WRHZKKKHEAAQJQ-INIZCTEOSA-N N-[(1S)-1-cyanoethyl]-4-[5-methyl-2-[[1-(oxan-4-yl)pyrazol-4-yl]amino]pyrimidin-4-yl]benzamide Chemical compound C1(N2N=CC(NC3=NC=C(C)C(=N3)C3=CC=C(C(=O)N[C@H](C#N)C)C=C3)=C2)CCOCC1 WRHZKKKHEAAQJQ-INIZCTEOSA-N 0.000 claims 1
- WYYKKKZFSVOSIW-KRWDZBQOSA-N N-[(1S)-1-cyanopropyl]-4-[2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]-5-methylpyrimidin-4-yl]benzamide Chemical compound N(C=1C=NN(C=1)CCO)C1=NC(=C(C)C=N1)C1=CC=C(C(=O)N[C@@H](CC)C#N)C=C1 WYYKKKZFSVOSIW-KRWDZBQOSA-N 0.000 claims 1
- XZVMTDZZIDRRAH-IBGZPJMESA-N N-[(1S)-1-cyanopropyl]-4-[5-methyl-2-[(1-piperidin-4-ylpyrazol-4-yl)amino]pyrimidin-4-yl]benzamide Chemical compound C1C(N2N=CC(NC3=NC=C(C)C(=N3)C3=CC=C(C(=O)N[C@@H](CC)C#N)C=C3)=C2)CCNC1 XZVMTDZZIDRRAH-IBGZPJMESA-N 0.000 claims 1
- UASQAPRBIMEDHE-FQEVSTJZSA-N N-[(1S)-1-cyanopropyl]-4-[5-methyl-2-[[1-(1-methylpiperidin-4-yl)pyrazol-4-yl]amino]pyrimidin-4-yl]benzamide Chemical compound CC[C@@H](C#N)NC(=O)C1=CC=C(C=C1)C2=NC(=NC=C2C)NC3=CN(N=C3)C4CCN(CC4)C UASQAPRBIMEDHE-FQEVSTJZSA-N 0.000 claims 1
- WFSQPUCXPSVZDM-NRFANRHFSA-N N-[(1S)-1-cyanopropyl]-4-[5-methyl-2-[[1-(2,2,6,6-tetramethyloxan-4-yl)pyrazol-4-yl]amino]pyrimidin-4-yl]benzamide Chemical compound C1(N2N=CC(NC3=NC(=C(C)C=N3)C3=CC=C(C(=O)N[C@@H](CC)C#N)C=C3)=C2)CC(C)(C)OC(C1)(C)C WFSQPUCXPSVZDM-NRFANRHFSA-N 0.000 claims 1
- VSAINCPLPOFVLV-IBGZPJMESA-N N-[(1S)-1-cyanopropyl]-4-[5-methyl-2-[[1-(oxan-4-yl)pyrazol-4-yl]amino]pyrimidin-4-yl]benzamide Chemical compound CC[C@@H](C#N)NC(=O)C1=CC=C(C=C1)C2=NC(=NC=C2C)NC3=CN(N=C3)C4CCOCC4 VSAINCPLPOFVLV-IBGZPJMESA-N 0.000 claims 1
- MWOVZVGNUMROIG-LJQANCHMSA-N N-[(S)-cyano(cyclopropyl)methyl]-4-[2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]-5-methylpyrimidin-4-yl]benzamide Chemical compound C1(=CN=C(N=C1C1=CC=C(C(=O)N[C@@H](C2CC2)C#N)C=C1)NC=1C=NN(C=1)CCO)C MWOVZVGNUMROIG-LJQANCHMSA-N 0.000 claims 1
- RSPBDCVRLCWDFT-JOCHJYFZSA-N N-[(S)-cyano(cyclopropyl)methyl]-4-[5-methyl-2-[(1-piperidin-4-ylpyrazol-4-yl)amino]pyrimidin-4-yl]benzamide Chemical compound CC1=CN=C(N=C1C2=CC=C(C=C2)C(=O)N[C@H](C#N)C3CC3)NC4=CN(N=C4)C5CCNCC5 RSPBDCVRLCWDFT-JOCHJYFZSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- FUKYYZIZPJCKQY-SURMOFKFSA-N [2H]C1=C([2H])C(C2=NC(NC3=CN(C4CC4)N=C3)=NC=C2Cl)=C([2H])C([2H])=C1C(N[C@@H](C)C#N)=O Chemical compound [2H]C1=C([2H])C(C2=NC(NC3=CN(C4CC4)N=C3)=NC=C2Cl)=C([2H])C([2H])=C1C(N[C@@H](C)C#N)=O FUKYYZIZPJCKQY-SURMOFKFSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024038370A JP7802106B2 (ja) | 2018-12-14 | 2024-03-12 | ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法 |
| JP2024038369A JP7802105B2 (ja) | 2018-12-14 | 2024-03-12 | ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/121165 | 2018-12-14 | ||
| PCT/CN2018/121165 WO2020118683A1 (en) | 2018-12-14 | 2018-12-14 | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
| PCT/CN2019/125552 WO2020119819A1 (en) | 2018-12-14 | 2019-12-16 | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024038369A Division JP7802105B2 (ja) | 2018-12-14 | 2024-03-12 | ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法 |
| JP2024038370A Division JP7802106B2 (ja) | 2018-12-14 | 2024-03-12 | ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022510925A JP2022510925A (ja) | 2022-01-28 |
| JP2022510925A5 JP2022510925A5 (https=) | 2022-11-04 |
| JPWO2020119819A5 true JPWO2020119819A5 (https=) | 2022-11-04 |
| JP7459094B2 JP7459094B2 (ja) | 2024-04-01 |
Family
ID=71076270
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530299A Active JP7459094B2 (ja) | 2018-12-14 | 2019-12-16 | ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法 |
| JP2024038369A Active JP7802105B2 (ja) | 2018-12-14 | 2024-03-12 | ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法 |
| JP2024038370A Active JP7802106B2 (ja) | 2018-12-14 | 2024-03-12 | ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024038369A Active JP7802105B2 (ja) | 2018-12-14 | 2024-03-12 | ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法 |
| JP2024038370A Active JP7802106B2 (ja) | 2018-12-14 | 2024-03-12 | ピラゾリル－アミノ－ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US12421213B2 (https=) |
| EP (1) | EP3877381A4 (https=) |
| JP (3) | JP7459094B2 (https=) |
| KR (2) | KR20250162926A (https=) |
| CN (7) | CN119118999A (https=) |
| AU (3) | AU2019399939B2 (https=) |
| BR (1) | BR112021011147A2 (https=) |
| CA (3) | CA3122872A1 (https=) |
| EA (1) | EA202191188A1 (https=) |
| IL (3) | IL314086A (https=) |
| MX (3) | MX2021006866A (https=) |
| SG (1) | SG11202105730TA (https=) |
| TW (3) | TWI889397B (https=) |
| WO (2) | WO2020118683A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110627775B (zh) * | 2019-10-24 | 2026-01-30 | 特科罗生物科技(成都)有限公司 | 一种小分子化合物 |
| TW202204333A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
| CN112661655B (zh) * | 2020-12-29 | 2022-02-18 | 江苏云朴医药新材料科技有限公司 | 一种1-氨甲基-1-环丙醇类化合物及其合成方法 |
| EP4577535A1 (en) * | 2022-08-22 | 2025-07-02 | Hangzhou Highlightll Pharmaceutical Co., Ltd. | Jak1/jak2/tyk2 inhibitors for topical treatment of dermatological diseases |
| CN115572269B (zh) * | 2022-10-08 | 2024-05-17 | 广州大学 | 一种n-三氟异丙基唑类和吲哚化合物及其制备方法 |
| WO2023151724A1 (zh) * | 2023-05-19 | 2023-08-17 | 凌科药业(杭州)有限公司 | 一种吡唑基-氨基-嘧啶基衍生物的晶型、制备方法及应用 |
| CN116751191B (zh) * | 2023-05-19 | 2025-09-16 | 凌科药业(杭州)有限公司 | 一种吡唑基-氨基-嘧啶基衍生物的晶型、制备方法及应用 |
| WO2024239282A1 (zh) | 2023-05-24 | 2024-11-28 | 凌科药业(杭州)有限公司 | 一种药物组合物、外用制剂及其制备方法、应用 |
| CN116983312B (zh) * | 2023-05-24 | 2024-07-05 | 凌科药业(杭州)有限公司 | 一种药物组合物、外用制剂及其制备方法、应用 |
| TW202545932A (zh) * | 2024-01-26 | 2025-12-01 | 大陸商凌科藥業(杭州)有限公司 | 一種吡唑基-胺基-嘧啶基衍生物的苯甲醯胺的晶型、製備方法及應用 |
| WO2025157231A1 (zh) * | 2024-01-26 | 2025-07-31 | 凌科药业(杭州)有限公司 | 一种吡唑基-氨基-嘧啶基衍生物的苯甲酰胺的晶型、制备方法及应用 |
| WO2025256636A1 (zh) * | 2024-06-13 | 2025-12-18 | 凌科药业(杭州)有限公司 | 含氮化合物及其制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| WO2007005643A2 (en) | 2005-07-01 | 2007-01-11 | Concert Pharmaceuticals Inc. | Novel aryloxyphenylpropanamines |
| WO2007005644A2 (en) | 2005-07-01 | 2007-01-11 | Concert Pharmaceuticals Inc. | Novel aryloxypropanamines |
| AU2006275702A1 (en) | 2005-07-29 | 2007-02-08 | Concert Pharmaceuticals Inc. | Novel pharmaceutical compounds |
| CA2616383C (en) | 2005-07-29 | 2015-06-09 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
| US8481538B2 (en) * | 2006-09-18 | 2013-07-09 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of c-Met and uses thereof |
| WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| WO2009064835A1 (en) * | 2007-11-16 | 2009-05-22 | Incyte Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
| AU2011328237A1 (en) * | 2010-11-09 | 2013-05-23 | Cellzome Limited | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
| WO2012143320A1 (en) * | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
| CN103781780B (zh) * | 2011-07-28 | 2015-11-25 | 赛尔佐姆有限公司 | 作为jak抑制剂的杂环基嘧啶类似物 |
| DE102011112978A1 (de) * | 2011-09-09 | 2013-03-14 | Merck Patent Gmbh | Benzonitrilderivate |
| KR101361149B1 (ko) * | 2012-07-17 | 2014-02-24 | 전남대학교산학협력단 | 가뭄 스트레스 저항성 관련 유전자 및 형질전환 식물체 |
| EP3080103B9 (en) * | 2013-12-11 | 2018-09-19 | Biogen MA Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| CN106349224A (zh) * | 2016-08-03 | 2017-01-25 | 山东大学 | 一种含有4‑氨基‑(1h)‑吡唑结构的jak激酶抑制剂及其制备方法和应用 |
| CN108864057B (zh) * | 2017-05-16 | 2020-03-31 | 山东大学 | 含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用 |
| WO2020206588A1 (en) * | 2019-04-08 | 2020-10-15 | Lynk Pharmaceuticals Co., Ltd. | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
| CN110330484B (zh) * | 2019-07-18 | 2022-08-26 | 中国药科大学 | 取代类苯基嘧啶衍生物作为jak激酶抑制剂或其可药用的盐、制备方法及用途 |
| CN110627775B (zh) * | 2019-10-24 | 2026-01-30 | 特科罗生物科技(成都)有限公司 | 一种小分子化合物 |
-
2018
- 2018-12-14 WO PCT/CN2018/121165 patent/WO2020118683A1/en not_active Ceased
-
2019
- 2019-12-13 TW TW113122616A patent/TWI889397B/zh active
- 2019-12-13 TW TW113122615A patent/TWI889396B/zh active
- 2019-12-13 TW TW108145807A patent/TWI866940B/zh active
- 2019-12-16 EP EP19896790.3A patent/EP3877381A4/en active Pending
- 2019-12-16 CN CN202411028139.7A patent/CN119118999A/zh active Pending
- 2019-12-16 BR BR112021011147-6A patent/BR112021011147A2/pt unknown
- 2019-12-16 IL IL314086A patent/IL314086A/en unknown
- 2019-12-16 CN CN202410365639.3A patent/CN118388457A/zh active Pending
- 2019-12-16 SG SG11202105730TA patent/SG11202105730TA/en unknown
- 2019-12-16 JP JP2021530299A patent/JP7459094B2/ja active Active
- 2019-12-16 KR KR1020257036502A patent/KR20250162926A/ko active Pending
- 2019-12-16 CN CN202410365633.6A patent/CN118290403A/zh active Pending
- 2019-12-16 WO PCT/CN2019/125552 patent/WO2020119819A1/en not_active Ceased
- 2019-12-16 CN CN202411028128.9A patent/CN118903141A/zh active Pending
- 2019-12-16 IL IL314084A patent/IL314084A/en unknown
- 2019-12-16 CA CA3122872A patent/CA3122872A1/en active Pending
- 2019-12-16 CA CA3230071A patent/CA3230071A1/en active Pending
- 2019-12-16 CN CN202411028121.7A patent/CN118955477A/zh active Pending
- 2019-12-16 CN CN201980076141.2A patent/CN113227074B/zh active Active
- 2019-12-16 CA CA3230060A patent/CA3230060A1/en active Pending
- 2019-12-16 CN CN202411028131.0A patent/CN118903142A/zh active Pending
- 2019-12-16 EA EA202191188A patent/EA202191188A1/ru unknown
- 2019-12-16 KR KR1020217019621A patent/KR102881668B1/ko active Active
- 2019-12-16 IL IL283968A patent/IL283968B2/en unknown
- 2019-12-16 AU AU2019399939A patent/AU2019399939B2/en active Active
- 2019-12-16 MX MX2021006866A patent/MX2021006866A/es unknown
-
2021
- 2021-06-10 MX MX2024005744A patent/MX2024005744A/es unknown
- 2021-06-10 MX MX2024005747A patent/MX2024005747A/es unknown
-
2022
- 2022-03-01 US US17/684,030 patent/US12421213B2/en active Active
- 2022-03-01 US US17/684,164 patent/US12595253B2/en active Active
-
2023
- 2023-09-10 US US18/244,276 patent/US12030870B2/en active Active
- 2023-09-10 US US18/244,281 patent/US11981663B2/en active Active
- 2023-09-24 US US18/372,115 patent/US12098142B2/en active Active
-
2024
- 2024-02-21 AU AU2024201125A patent/AU2024201125B2/en active Active
- 2024-02-21 AU AU2024201128A patent/AU2024201128B2/en active Active
- 2024-03-12 JP JP2024038369A patent/JP7802105B2/ja active Active
- 2024-03-12 JP JP2024038370A patent/JP7802106B2/ja active Active
- 2024-08-15 US US18/805,713 patent/US20250115586A1/en active Pending